Madrigal Pharmaceuticals Inc.
MDGLHeld by 11 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying11 funds opened new positions. Next phase3 readout (Resmetirom): Mar 2026. Short interest: 19.3% of float.
Held by 11 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying11 funds opened new positions. Next phase3 readout (Resmetirom): Mar 2026. Short interest: 19.3% of float.
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)
11 specialist funds hold MDGL with a Phase 3 in 172 days for Resmetirom (NASH, Cirrhosis, Liver)
+2 more upcoming catalysts
Position history (shares)
Perceptive Advisors fully exited MDGL despite 11 specialist funds remaining holders — including RA Capital, OrbiMed, and Baker Bros. — creating a notable divergence from the broader specialist consensus.
7 quarters
Feb 17, 2026
$2.6B
4 funds
Mar 16, 2026
$1.1B
1 fund
May 15, 2026
$3.3B
5 funds
May 29, 2026
$0
0 funds
-100% total institutional value over 23 quarters
Short Shares
3.78M
Change
-3.0%
Days to Cover
14.1
% of Float
19.3%
Settlement
Jun 15, 2026
Short interest over 10 periods
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.
# Investment Summary: Resmetirom (MDGL) Clinical Evidence Resmetirom, Madrigal's lead therapeutic candidate, has demonstrated clinical efficacy in treating metabolic dysfunction-associated fatty liver disease (MASLD), with published evidence supporting its mechanism in reducing hepatic steatosis and inflammation markers. The clinical practice implications outlined in this peer-reviewed publication validate the drug's positioning within the MASLD treatment landscape, potentially expanding addressable patient populations beyond the metabolic steatohepatitis (MASH) indication and strengthening commercial adoption pathways. **Investor relevance:** This European journal publication provides third-party clinical validation that supports market penetration in international markets, particularly Europe, and reinforces the clinical rationale for broader MASLD indication expansion—both critical factors for peak sales projections and market exclusivity strategy.
# Investment Summary: Madrigal Pharmaceuticals (MDGL) - Resmetirom PK Study **Clinical/Commercial Relevance:** This pharmacokinetic and metabolic profiling study of resmetirom (MDGL's lead THR-β selective agonist) provides foundational safety and dosing data necessary for regulatory submissions and dose optimization in NASH/MASH patients. The mass balance and metabolic characterization work establishes the drug's absorption, distribution, and elimination pathways—critical information for identifying potential drug-drug interactions and supporting clinical efficacy claims in ongoing Phase 3 trials. Understanding resmetirom's metabolism is essential for determining dosing schedules and predicting how it performs in hepatically-impaired populations, directly impacting the commercial viability of this indication given the liver disease patient demographics. **Why This Matters:** This foundational PK data strengthens MDGL
# Investment Summary: Madrigal Pharmaceuticals (MDGL) - Resmetirom Formulation Advancement Researchers have developed cocrystal formulations of resmetirom (MDGL's lead THR-β selective agonist) to improve its poor aqueous solubility, a known formulation challenge for oral bioavailability. Enhanced dissolution could reduce pill burden, improve patient compliance, and potentially expand the addressable patient population for non-alcoholic steatohepatitis (NASH) treatment. This formulation optimization may provide competitive advantages in manufacturing scalability and commercial margins if adopted in future product iterations, though near-term impact depends on whether MDGL integrates these findings into ongoing or planned clinical programs.
# Investment Summary: Madrigal Pharmaceuticals (MDGL) This analytical chemistry paper describes a validated reverse-phase HPLC method for quantifying rezdiffra (MGL-3196) in raw material and finished drug formulations. The work supports manufacturing scale-up and quality control standardization—routine but necessary for commercial production and regulatory compliance as the drug moves through post-launch phases. For investors, this indicates infrastructure maturation for sustained supply chain reliability, though the research itself does not address clinical efficacy, market adoption, or competitive positioning.
# Investment Summary: Madrigal Pharmaceuticals (MDGL) Resmetirom demonstrated quantitative regression of liver fibrosis in MAESTRO-NASH, with histologic improvements supporting the drug's mechanism as a THR-β agonist for NASH treatment. This exploratory endpoint data strengthens the clinical profile beyond standard NASH endpoints and could support FDA approval discussions, given the significant unmet need in progressive fibrosis stages. Commercial viability depends on regulatory interpretation of these histologic findings and competitive positioning relative to other pipeline NASH candidates, particularly regarding disease stage penetration and label claims.
Start free trialfor share counts, dollar values & AI analysis
120 more position changes — start your free trial to see dollar values and AI analysis for all of them.
Track specialist biotech funds, insider signals, and AI analysis
Start 14-Day Free TrialGet free weekly alerts on fund moves and catalysts: